NK cell culture medium and preparation method
By adding lymphocyte serum-free culture medium and immune cell serum substitute to NK cell culture medium, combined with protransduction reagents, the infection efficiency of lentivirus or retrovirus is improved, and the integration of CAR genes in the prior art was solved. The problem of low efficiency achieves efficient NK cell amplification and killing ability.
Patent Information
- Application Number
- CN202411587163.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-08
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-11-08
AI Technical Summary
In the prior art, the infection efficiency of lentivirus/retrovirus on NK cells is very low, resulting in low CAR gene integration efficiency, affecting the anti-tumor killing ability of NK cells.
Provide a complete medium including lymphocyte serum-free medium and immune cell serum substitute, combined with a protransduction agent, for improving the infection efficiency of lentivirus or retrovirals to NK cells by culturing in complete medium NK cells were added with viruses and protransduction reagents, which significantly increased the CAR positivity rate and amplification fold.
It improves the CAR positive rate of lentivirus-infected NK cells, significantly increases the purity and killing efficiency of NK cells, reduces production costs, and is suitable for large-scale production.
Smart Images

Figure CN119082024A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the biological field, and in particular to a culture medium for NK cells and a preparation method thereof. Background Art
[0002] NK cells are a type of lymphocytes that have a strong killing effect on tumor cells and are MHC-independent. Their recognition of tumor cells mainly depends on the cross-regulation of their surface activating receptors and inhibitory receptors. After recognizing tumor cells, NK cells kill tumor cells through multiple pathways, such as releasing killing mediators perforin and granzyme to cause target cell apoptosis, expressing membrane TNF family molecules to induce target cell apoptosis, and antibody-dependent cytotoxicity. Modifying NK cells with CAR is expected to enhance their ability to target and kill tumor cells and develop effector cells with strong anti-tumor effects.
[0003] The most commonly used method on the market to stably integrate the CAR gene into cells is the lentivirus / retrovirus method. Currently, the methods for integrating the CAR gene into the T cell genome in CAR T cell drugs that have been marketed both domestically and internationally all use the lentivirus / retrovirus method, but the infection efficiency of lentivirus / retrovirus on NK cells is very low. Summary of the invention
[0004] In view of the above-mentioned shortcomings of the prior art, an object of the present invention is to provide a culture medium and a preparation method of NK cells to solve the problems in the prior art.
[0005] To achieve the above-mentioned object and other related objects, the present invention provides a complete culture medium for culturing NK cells. Based on the total volume of the complete culture medium, the complete culture medium comprises the following components: a lymphocyte serum-free culture medium with a volume fraction of 85-98%, an immune cell serum replacement (SR) with a volume fraction of 2-15%, and IL-2 with a final concentration of 180-220 IU / ml.
[0006] The present invention also provides use of the complete culture medium in culturing NK cells or preparing a lentiviral or retroviral transduction reagent.
[0007] The present invention also provides a method for culturing NK cells, wherein the preparation method comprises culturing NK cells using the complete culture medium.
[0008] The present invention also provides a method for transducing NK cells with a lentivirus or a retrovirus, the method comprising the following steps: adding a lentivirus or a retrovirus to the NK cells obtained by the aforementioned culture method, and adding a transduction-promoting reagent, and obtaining NK cells transduced with the lentivirus or the retrovirus after culture.
[0009] As described above, the culture medium and preparation method of NK cells of the present invention have the following beneficial effects: the culture medium formula combined with the transduction-promoting reagent greatly improves the efficiency of lentivirus infection of NK cells. Flow cytometer detection shows that compared with the culture medium formula with a lower CAR positivity rate, the CAR positivity rate of the highest culture medium formula is increased by 3-4 times, the amplification multiple is high, the NK cell purity is high, and the CAR positivity rate is significantly increased, which greatly reduces the cost. The method is simple, efficient, and conducive to large-scale production. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 Shown is a graph of the expansion fold during the NK cell culture process of the present invention.
[0011] Figure 2 Shown is a graph of the lentiviral transduction efficiency of the present invention.
[0012] Figure 3 Shown is a graph of NK cell killing efficiency of the present invention.
[0013] Figure 4 Shown are the results of perforin secretion detection after co-culture of the CAR-NK cells of the present invention and K562 cells. DETAILED DESCRIPTION
[0014] The present invention provides a complete culture medium for culturing NK cells. The complete culture medium comprises the following components based on the total volume of the complete culture medium: a lymphocyte serum-free culture medium with a volume fraction of 85-98%, an immune cell serum substitute (SR) with a volume fraction of 2-15%, and an interleukin with a final concentration of 50-500 IU / ml.
[0015] In certain embodiments of the present invention, the volume fraction of the lymphocyte serum-free culture medium is selected from any of the following ranges: 85-87%, 87-89%, 89-91%, 91-93%, 93-95%, 95-98%.
[0016] In certain embodiments of the present invention, the lymphocyte serum-free culture medium is HIPP-T009 lymphocyte serum-free culture medium with a product number of FG0103801 or RG0101302 produced by Shanghai Bio-Gene Biotechnology Co., Ltd.
[0017] In certain embodiments of the present invention, the volume fraction of the immune cell serum substitute is selected from any of the following ranges: 2-5%, 5-7%, 7-9%, 9-11%, 11-13%, 13-15%.
[0018] In certain embodiments of the present invention, the brand and product number of the immune cell serum replacement are Gibco and A2596101, respectively.
[0019] In certain embodiments of the present invention, the interleukin is selected from any one or more combinations of IL-2, IL-15, IL-18, and IL-21.
[0020] In certain embodiments of the present invention, the interleukin is selected from IL-2 with a final concentration of 180-220 IU / ml.
[0021] In certain embodiments of the present invention, the final concentration of IL-2 is selected from any of the following ranges: 100-150 IU / ml, 150-180 IU / ml, 180-190 IU / ml, 190-200 IU / ml, 200-210 IU / ml, 210-220 IU / ml, 220-300 IU / ml, 300-400 IU / ml, 400-500 IU / ml.
[0022] In certain embodiments of the present invention, the complete culture medium is selected from any of the following formulas: 1) 95% lymphocyte serum-free medium, 5% serum replacement, and IL-2 at a final concentration of 200 IU / ml; 2) 95% lymphocyte serum-free medium, 5% serum replacement, and 400 IU / ml IL-2; 3) 98% lymphocyte serum-free medium, 2% serum replacement, and 200 IU / ml IL-2; 4) 98% lymphocyte serum-free medium, 2% serum replacement, and 400 IU / ml IL-2.
[0023] The present invention also provides use of the complete culture medium in culturing NK cells or preparing a lentiviral or retroviral transduction reagent.
[0024] The lentivirus or retrovirus transduction reagent is a reagent used in the process of transducing lentivirus or retrovirus into NK cells to improve the transduction efficiency of lentivirus or retrovirus.
[0025] The present invention also provides a method for culturing NK cells, wherein the preparation method comprises culturing NK cells using the complete culture medium.
[0026] The NK cells are commercial NK cells or NK cells obtained by sorting from PBMC.
[0027] In certain embodiments of the present invention, before using the complete medium to culture NK cells, the method further comprises co-culturing IL21-41BBL-K562 feeder cells with NK cells to activate NK cells.
[0028] The number of IL21-41BBL-K562 trophoblasts is in excess relative to the number of NK cells. In certain embodiments of the present invention, the number of IL21-41BBL-K562 trophoblasts is more than 1.5 times the number of NK cells, preferably more than 2 times, for example, more than 2 times, 2.5 times or 3 times.
[0029] In certain embodiments of the present invention, when NK cells are cultured using the complete culture medium, the initial cell concentration of NK cells is 1-3×10^6 cells / ml, preferably, 1.25-2.5×10^6 cells / ml.
[0030] In certain embodiments of the present invention, the time for culturing NK cells using the complete medium is 5 to 8 days.
[0031] In certain embodiments of the present invention, during the process of culturing NK cells using the complete culture medium, complete culture medium is supplemented every 2 to 3 days until the NK cell density is 5×10^5 cells / ml to 1×10^6 cells / ml.
[0032] In certain embodiments of the present invention, the culture conditions are 36-38° C. and 4.5-5.5% CO 2 .
[0033] The present invention also provides a method for transducing NK cells with a lentivirus or a retrovirus, the method comprising the following steps: adding a lentivirus or a retrovirus to the NK cells obtained by the aforementioned culture method, and adding a transduction-promoting reagent, and obtaining NK cells transduced with the lentivirus or the retrovirus after culture.
[0034] In certain embodiments of the present invention, the lentivirus or retrovirus and its transduction concentration are not specifically limited in the present invention, and those skilled in the art can determine it according to actual needs or experience.
[0035] The transduction-promoting agent may be a conventional viral infection enhancer in the prior art, such as the agent with the miltenyi product number 130-111-163.
[0036] The final concentration of the transduction-promoting reagent is 5-10 μg / ml.
[0037] In one embodiment, the cells are cultured for 7 to 15 days after transduction.
[0038] In one embodiment, complete medium can be added during transduction, and added every 2-3 days.
[0039] The present invention also provides a cell prepared by the method, wherein the polynucleotide of the lentivirus or retrovirus is integrated into the genome of the cell.
[0040] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.
[0041] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms.
[0042] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention. Example 1
[0043] Cryopreserved PBMC (peripheral blood mononuclear cells) from healthy donors were used for NK cell expansion and lentiviral transduction, which involved several steps including PBMC and IL21-41BBL-K562 trophoblast cell recovery, NK cell sorting, trophoblast cell addition, lentiviral transduction, and expansion culture, as follows: 1) PBMC and IL21-41BBL-K562 trophoblast cell recovery: cryopreserved PBMC and IL21-41BBL-K562 trophoblast cells from healthy donors (Jiangsu Puxin Biotechnology Co., Ltd., HG-FEC001-RG) were recovered in a 37°C water bath, and 5-10 times the volume of preheated sorting buffer (Miltenyi Biotec BV&Co. KG: 200-070-025) was added to wash the PBMCs. After centrifugation at 400g for 10 min, the supernatant was discarded and the cells were counted.
[0044] 2) Cell sorting: After cell counting, add 20-30 ml sorting buffer and mix well. Centrifuge at 400 g for 10 min. Add sorting buffer to the cell pellet at 80 μl / 1E7 total cells according to the number of PBMC cells. Add CD3 sorting magnetic beads at 80 μl / 1E7 total cells. Incubate at 4°C for 15-20 min. After incubation, add 20-30 ml sorting buffer. Centrifuge at 300 g for 15 min. Resuspend with 500 μl sorting buffer after centrifugation. Sorting is performed on a sorting column. The liquid retained from the sorting column is the CD3- cells.
[0045] 3) Addition of IL21-41BBL-K562 trophoblast cells: Add IL21-41BBL-K562 trophoblast cells according to the ratio of CD3-cell count to IL21-41BBL-K562 trophoblast cells = 1:2, and add culture medium until the CD3-cell density is 1.25~2.5E6 cells / ml. Trophoblast cells do not need to be separated in the later stage. During transduction, the activity of trophoblast cells is already very low or the proportion is very small, which will not affect the subsequent experimental process.
[0046] 4) Cell expansion: The cells were cultured for 10-14 days in complete medium containing the following different medium formulas. SR is a serum replacement (Gibco, CTS, Immune cell SR: A2596101). Cytokines include one or more combinations of IL-2 (100-500 IU / ml) and IL-15 (50-150 IU / ml): Formula 1: HIPP-T009 serum-free medium (Bei Anji, FG0103801) + SR (final concentration 5%) + IL-2 (final concentration 200 IU / ml); Formula 2: HIPP-T009 serum-free medium + SR (final concentration 5%) + IL-2 (final concentration 400 IU / ml); Formula 3: HIPP-T009 serum-free medium + SR (final concentration 2%) + IL-2 (final concentration 200 IU / ml); Formula 4: HIPP-T009 serum-free medium + SR (final concentration 2%) + IL-2 (final concentration 400 IU / ml); Formulation 5: CTS NK-Xpander Medium (Gibco, A5019001) + SR (final concentration 5%) + IL-2 (final concentration 200 IU / ml); Formulation 6: CTS NK-Xpander Medium (Gibco, A5019001) + SR (final concentration 5%) + IL-2 (final concentration 400 IU / ml); Formulation 7: CTS NK-Xpander Medium (Gibco, A5019001) + SR (final concentration 2%) + IL-2 (final concentration 200 IU / ml); Formulation 8: CTS NK-Xpander Medium (Gibco, A5019001) + SR (final concentration 2%) + IL-2 (final concentration 400 IU / ml); Formulation 9: NK MACS CD Medium (Miltenyi Biotec, 130-114-429) + SR (final concentration 5%) + IL-2 (200 IU / ml); Formulation 10: NK MACS CD Medium (Miltenyi Biotec, 130-114-429) + SR (final concentration 5%) + IL-2 (400 IU / ml); Formulation 11: NK MACS CD Medium (Miltenyi Biotec, 130-114-429) + SR (final concentration 2%) + IL-2 (200 IU / ml); Formulation 12: NK MACS CD Medium (Miltenyi Biotec, 130-114-429) + SR (final concentration 2%) + IL-2 (400 IU / ml); Formulation 13: NK MACS CD Medium (Miltenyi Biotec, 130-114-429) + SR (final concentration 2%) + IL-2 (400 IU / ml) + IL15 (5 ng / ml); During this period, complete culture medium was added every 2 to 3 days to 5E5 cells / ml~1E6 cells / ml according to the cell density, and lentiviral transduction was performed on the 5th to 8th day of culture.
[0047] 5) Lentiviral transduction: Take NK cells cultured for 5-8 days for lentiviral transduction. The lentiviral CAR is anti CD19CAR, and the sequence and preparation method are the same as those of the domestic patent with application number CN201910625785.4. Add the corresponding amount of virus and Vectofusin-1 (5~10ug / ml, manufacturer: miltenyi, catalog number 130-111-163).
[0048] 6) Cell harvesting: NK cells were harvested after 14 days of culture. The expansion multiples were monitored during the culture process. The NK cell expansion data of each group of CAR-NK cells after 14 days of culture are shown in the following table. Figure 1 As shown, the results show that the NK cell expansion multiples using the medium of formula 2 according to the above operation are close to 10,000 times (9,622 times). The cells harvested after 14 days of culture were sent to flow cytometry to detect the NK cell transduction efficiency.
[0049] 7) Streaming results: Figure 2 As shown, the NK cell transduction efficiency using the culture medium of formula 2 according to the above operation is the highest, which can reach more than 40%. Compared with the culture medium formula with the lowest transduction efficiency (formulation 7), the transduction efficiency is increased by 3 to 4 times.
[0050] Example 2 Cell killing experiment 1) Take 100 μl of target cell K562 cell suspension and group them into "target cell spontaneous release group" (i.e., a system in which target cells are cultured alone and are not lysed during detection, and only the spontaneously released LDH is detected), "maximum release group" (i.e., a group in which all target cells cultured alone are lysed and the released LDH is detected) and "killing effect group" (i.e., a group in which target cells are co-incubated with effector cells), and add them into a 96-well round-bottom plate, with 3 parallel wells set up for each group.
[0051] 2) Take 100 μl of effector cell CAR-NK and Mock NK cells respectively, and add them to the wells of the 96-well round-bottom plate corresponding to the "killing effector group", set up 3 parallel wells in each group, mix them evenly, and the effector-target ratio is 5:1. At the same time, set up the "effector cell spontaneous release group", that is, only add effector cells, do not lyse them during detection, and only detect their spontaneously released LDH.
[0052] 3) Add 100 μl of culture medium to the “spontaneous release group”, “maximum release group” and “killing effect group” respectively to make the final volume 200 μl.
[0053] 4) Place the culture plate in a 37±1℃, 5±0.5% CO2 incubator for incubation. After about 16 hours, perform lysis detection on the "maximum release group" and measure the OD value at a wavelength of 492nm. Complete the on-machine detection within 10 minutes after the reaction is terminated.
[0054] 5) Calculation formula: Killing rate %=(killing effector group-target cell spontaneous release group-effector cell spontaneous release group) / (maximum release group-target cell spontaneous release group).
[0055] 6) Results The killing efficiency of NK cells cultured with different culture formulas on K562 Figure 3 As shown, the results showed that the cell killing effects of formula 2, formula 3 and formula 4 were higher than those of the other groups. The final killing efficiencies measured by the LDH release method were 78.8%, 76.5% and 77.7%, respectively. It can be concluded that the CAR-NK cells cultured with formula 2, formula 3 and formula 4 have a strong killing effect on target cells.
[0056] Example 3 Detection of perforin secretion after co-culture of CAR-NK cells and K562 cells 1) Take 100 μl of target cell K562 cell suspension and add it to a 96-well round-bottom plate, setting up 3 parallel wells.
[0057] 2) Take 100 μl of effector CAR-NK cells and add them to the wells of a 96-well round-bottom plate containing target cells, mix well, and set the effector-target ratio to 5:1 as the co-incubation group. At the same time, set up an "effect cell self-incubation group", that is, only add effector cells. Set up 3 parallel wells for each group.
[0058] 3) Add 100 μl of culture medium to each group to make the final volume 200 μl.
[0059] 4) After the culture plate was placed in a 37±1°C, 5±0.5% CO2 incubator for about 20 hours, the supernatant of the co-incubation group and the effector cell self-incubation group was collected for perforin factor secretion detection using a perforin detection kit.
[0060] The secretion amount of perforin in each group is obtained by subtracting the value of the self-incubation group from the value of the co-incubation group. The specific results are as follows Figure 4 As shown, it can be concluded that the CAR-NK cells cultured with Formula 2, Formula 3 and Formula 4 have a stronger ability to promote the release of perforin protein levels when co-cultured with target cells.
[0061] The above examples are for the purpose of illustrating the embodiments disclosed by the present invention and are not to be construed as limiting the present invention. In addition, the various modifications listed herein and the variations of the methods in the invention are obvious to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been specifically described in conjunction with various specific preferred embodiments of the present invention, it should be understood that the present invention should not be limited to these specific embodiments. In fact, various modifications as described above that are obvious to those skilled in the art to obtain the invention should be included within the scope of the present invention.
Claims
1. Use of the complete medium described below in culturing NK cells or preparing lentiviral or retroviral transduction reagents: based on the total volume of the complete medium, the complete medium comprises the following components: a lymphocyte serum-free medium with a volume fraction of 85-98%, an immune cell serum substitute with a volume fraction of 2-15%, and an interleukin with a final concentration of 100-500 IU / ml. The lymphocyte serum-free medium is the HIPP-T009 lymphocyte serum-free medium with a product number of FG0103801 or RG0101302 produced by Shanghai Beianji Biotechnology Co., Ltd.
2. The use according to claim 1, It is characterized in that The interleukin is selected from IL-2 with a final concentration of 180-220 IU / ml.
3. The use according to claim 1, It is characterized in that The complete culture medium is selected from any of the following formulas: 1) 95% lymphocyte serum-free medium, 5% serum replacement, and IL-2 at a final concentration of 200 IU / ml; 2) 95% lymphocyte serum-free medium, 5% serum replacement, and 400 IU / ml IL-2; 3) 98% lymphocyte serum-free medium, 2% serum replacement, and 200 IU / ml IL-2; 4) 98% lymphocyte serum-free medium, 2% serum replacement, and 400 IU / ml IL-2.
4. A method for culturing NK cells, It is characterized in that The culture method includes co-culturing IL21-41BBL-K562 trophoblast cells with NK cells to activate NK cells, and then using the complete medium described below to culture the NK cells. Based on the total volume of the complete medium, the complete medium includes the following components: a lymphocyte serum-free medium with a volume fraction of 85-98%, an immune cell serum substitute with a volume fraction of 2-15%, and an interleukin with a final concentration of 100-500 IU / ml. The lymphocyte serum-free medium is the HIPP-T009 lymphocyte serum-free medium with a product number of FG0103801 or RG0101302 produced by Shanghai Bei'anji Biotechnology Co., Ltd.
5. The culture method according to claim 4, It is characterized in that The interleukin is selected from IL-2 with a final concentration of 180-220 IU / ml, or the complete culture medium is selected from any of the following formulas: 1) 95% lymphocyte serum-free medium, 5% serum replacement, and IL-2 at a final concentration of 200 IU / ml; 2) 95% lymphocyte serum-free medium, 5% serum replacement, and 400 IU / ml IL-2; 3) 98% lymphocyte serum-free medium, 2% serum replacement, and 200 IU / ml IL-2; 4) 98% lymphocyte serum-free medium, 2% serum replacement, and 400 IU / ml IL-2.
6. The culture method according to claim 4, It is characterized in that The cell number of the IL21-41BBL-K562 trophoblast cells is in excess relative to the cell number of NK cells.
7. The culture method according to claim 6, It is characterized in that Also includes any one or more of the following features: 1) The number of IL21-41BBL-K562 trophoblast cells is 1.5 to 2.5 times the number of NK cells; 2) When culturing NK cells using the complete medium, the initial cell concentration of NK cells is 1-3×10^6 cells / ml; 3) The NK cells are cultured using the complete medium for 5 to 8 days; 4) During the process of culturing NK cells using the complete medium, the complete medium is supplemented every 2 to 3 days until the NK cell density reaches 5×10^5 cells / ml to 1×10^6 cells / ml; 5) Culture conditions are 36-38°C, 4.5-5.5% CO 2 .
8. A method for transducing NK cells using lentivirus or retrovirus, It is characterized in that The method comprises the following steps: adding a lentivirus or a retrovirus to the NK cells obtained by the culture method according to any one of claims 4 to 7, and adding a transduction-promoting reagent, and obtaining NK cells transduced with the lentivirus or the retrovirus after culture.
9. The method according to claim 8, It is characterized in that The final concentration of the transduction-promoting reagent is 5-10 μg / ml.
10. The method according to claim 8, It is characterized in that Culture cells for 7-15 days after transduction and / or supplement with complete medium during transduction.
Citation Information
Patent Citations
CAR-NK cell and preparation method thereof
CN115521915A
Resuscitation and culture method of ROBO1 CAR NK cells
CN116254233A
Kit for preparing NK cells and application of kit in preparation of umbilical cord blood-derived NK cells
CN118126946A
Preparation method and application of clinical-grade CAR-NK cell drug injection
CN118308304A
Serum-free culture medium for NK cells
CN118667759A
